1. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation
by Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, and Alvaro Alonso
BloodAdv
Volume 2(3):
February 13, 2018
© 2018 by The American Society of Hematology

2. Professional illustration by Patrick Lane, ScEYEnce Studios.
Surbhi Shah et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

3. Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: rivaroxaban vs warfarin users.
Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: rivaroxaban vs warfarin users.
Surbhi Shah et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: dabigatran vs warfarin users.
Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: dabigatran vs warfarin users.
Surbhi Shah et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: apixaban vs warfarin users.
Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: apixaban vs warfarin users.
Surbhi Shah et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology